HC Wainwright Reiterates “Neutral” Rating for Ventyx Biosciences (NASDAQ:VTYX)

HC Wainwright reissued their neutral rating on shares of Ventyx Biosciences (NASDAQ:VTYX) in a report published on Tuesday morning, Benzinga reports. They currently have a $6.00 target price on the stock.

Separately, Oppenheimer dropped their target price on shares of Ventyx Biosciences from $12.00 to $10.00 and set an outperform rating on the stock in a research note on Thursday, June 6th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $15.75.

Ventyx Biosciences Price Performance

NASDAQ:VTYX opened at $2.08 on Tuesday. The firm has a 50-day moving average of $2.99 and a 200-day moving average of $4.14. The company has a market cap of $146.64 million, a PE ratio of -0.64 and a beta of 0.39. Ventyx Biosciences has a one year low of $1.87 and a one year high of $38.20.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.05. During the same quarter in the previous year, the firm earned ($0.68) EPS. On average, equities research analysts expect that Ventyx Biosciences will post -2.31 earnings per share for the current fiscal year.

Institutional Trading of Ventyx Biosciences

A number of institutional investors have recently modified their holdings of VTYX. Farallon Capital Management LLC purchased a new stake in shares of Ventyx Biosciences during the 1st quarter valued at approximately $17,435,000. Redmile Group LLC lifted its stake in shares of Ventyx Biosciences by 944.4% during the 1st quarter. Redmile Group LLC now owns 2,164,126 shares of the company’s stock valued at $11,903,000 after buying an additional 1,956,923 shares in the last quarter. Opaleye Management Inc. purchased a new stake in shares of Ventyx Biosciences during the 4th quarter valued at approximately $2,816,000. First Light Asset Management LLC purchased a new stake in shares of Ventyx Biosciences during the 1st quarter valued at approximately $3,437,000. Finally, Ikarian Capital LLC lifted its stake in shares of Ventyx Biosciences by 8,483.8% during the 1st quarter. Ikarian Capital LLC now owns 507,647 shares of the company’s stock valued at $2,792,000 after buying an additional 501,733 shares in the last quarter. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.